The discussion on biomarker testing practices for patients with non–small cell lung cancer turns its focus to the metastatic setting.
Zenocutuzumab Earns FDA Priority Review in NRG1+ NSCLC, Pancreatic Cancer
Data from the phase 1/2 eNRGy trial support the biologics license application for zenocutuzumab in NRG1-positive NSCLC and PDAC.
Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery
Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.
Glecirasib Shows Promising Efficacy in KRAS G12C+ Advanced NSCLC
Those who have been previously treated for KRAS G12C–mutated advanced NSCLC may benefit from treatment with glecirasib.
Combatting Stigmatization to Increase Lung Cancer Screening Access
Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN, discusses how LungTalk, a health communication and decision support tool, may spread awareness and knowledge surrounding lung cancer screening.
Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC
Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.
Tislelizumab Earns European Approval in Non–Small Cell Lung Cancer
A series of phase 3 findings support the European approval of tislelizumab as a first-line and second-line treatment for non–small cell lung cancer.